Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component

Chronic Low Back Pain Clinical Trial

Official title:

Randomized Double-blind Study Comparing the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01166048
• Other study ID #: SPDP-01
• Status: Completed
• Phase: Phase 4
• First received: May 18, 2010
• Last updated: July 29, 2014
• Start date: May 2010
• Est. completion date: June 2014

Study information

• Verified date: July 2014
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Agency for Health and Food SafetyAustria: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

Objective:

The objective of this study is to compare the efficacy of duloxetine in the treatment of patients with chronic low back pain with a radicular component to placebo.

Study hypothesis:

Duloxetine is a new substance now in use for the treatment of neuropathic pain. It has proven its efficacy in diabetic peripheral neuropathy and fibromyalgia in several trials. The investigators therefore hypothesize that duloxetine will be efficacious in patients with chronic low back pain and a radicular component.

Study Rationale:

Chronic low back pain is an extremely common diagnosis. However, therapeutic options for the condition are limited and therapy remains difficult. Duloxetine has proven its efficacy in patients with neuropathic pain and may also be useful in chronic low back pain. If the investigators are able to show a benefit for patients in the duloxetine arm, the substance may constitute a further treatment alternative in chronic low back pain.

Study Design:

Prospective, randomized, double-blind placebo-controlled cross over study. Patients will be administered duloxetine for 4 weeks followed by a 2 week wash-out phase after which they will be medicated with placebo for 4 weeks. A second group of patients will receive the medication in reversed order. The primary study endpoint is constituted the weekly mean of VAS-Score in the last week of each treatment period. Secondary endpoints are defined as use of rescue medication, Beck Depression Inventory score, Health related Quality of Life SF-36 score and side effects/adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Low back pain ( below L1)

• Chronic pain, >6 months

• Visual Analogue Scale (VAS) = 5

• Back pain with radicular component defined as pain with a burning, tingling sensation within the anatomic distribution of the nerve root and diagnosed by painDETECT questionnaire

• Failed back surgery

Exclusion Criteria:

• Current mood disorder (dysthymia, bipolar mood disorder)

• Major Depression > 12 months (Beck Depression Inventory Score = 18)

• History of a psychoactive substance use disorder within the preceding 12 months

• Major coexisting medical illness (e.g. severe heart failure, pulmonary hypertension, renal insufficiency)

• Glaucoma

• Acute myocardial infarction

• uncontrolled hypertension

• Prostate hyperplasia

• History of convulsion

• Pregnancy; women of childbearing age will be required to use contraceptives during the duration of the study. Furthermore a pregnancy test will be performed prior to the beginning of the study and once a month during the study period.

• Participation in a clinical trial in the 3 weeks preceding the study

• Allergy to study medication

• Use of the following medication:

• opioids except for tramadol,

• benzodiazepines other than indicated at low doses for sleep disorders

• antineuropathic medication including except for that specified in the study protocol

• muscle relaxants

• antidepressants other than indicated at low doses for sleep disorders

• NSAID, Paracetamol

• non-selective MAO-Inhibitors

• Fluvoxamine, Ciprofloxacin, Enoxacin

• Selective Serotonin-reuptake Inhibitors (SSRI)

if tapering of these drugs is impossible before inclusion.

• Impaired kidney function (Creatinine > 1.5mg/dl)

• Impaired hepatic function (GOT, GPT >2 fold standard levels)

• Patients who are not able to understand the study measures and are not able to complete pain assessment forms.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Back Pain
• Chronic Low Back Pain
• Low Back Pain

Intervention

Drug:
• Duloxetine
Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo) day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg
• Duloxetine
2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.

Locations

Country	Name	City	State
Austria	Department of Special Anesthesia and Pain Therapy, Medical University of Vienna, AKH Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weekly mean pain intensity in study phase I (Visual analogue score, units 1-10)	Operationally a VAS is a horizontal line, 100 mm in length, anchored by word descriptors at each end (left= no pain, right=worst imaginable pain).The patient marks the current subjective pain intensity on the scale. This is converted to a numeric value by measurement from the left side of the scale. (Units 1-10)	Week 4 of study period	No
Primary	Weekly mean pain intensity in study phase II (Visual analogue score, units 1-10)		Week 10 of study period	No
Secondary	Use of rescue medication in study phase I	Patients will be allowed Metamizol (500mg up to 3g per day) and Tramadol drops (20 ggt. up to 6 times per day) as rescue medication. Rescue medication will be recorded daily in a patient diary. Use of rescue medication will be scored as follows: 0=no rescue medication; 1=metamizol; 2=tramadol	Use of rescue medication in week 4 of study period	No
Secondary	Beck Depression Inventory score in phase I of study period	Subjects will be asked to perform the Beck Depression Inventory at screening and at week 4.	Beck Depression Inventory score at week 4 of study period	No
Secondary	Health related Quality of Life SF-36 score in phase I of study period	Subjects will be asked to fill out the Health related Quality of Life SF-36 questionnaire at screening and at the end of each treatment period (placebo and verum)	Health related Quality of Life SF-36 score at week 4 of study period.	No
Secondary	painDetect score in phase I of study period	Subjects will be asked to complete the painDetect questionnaire at screening and the end of each treatment period (placebo and verum).	painDetect score at week 4 of study period.	No
Secondary	Use of rescue medication in phase II of study period		Use of rescue medication in week 10 of study period.	No
Secondary	Beck Depression Inventory score in phase II of study period		Beck Depression Inventory score at week 10 of study period.	No
Secondary	Health related Quality of Life SF-36 score in phase II of study period.		Health related Quality of Life SF-36 score at week 10 of study period.	No
Secondary	painDetect score in phase II of study period		painDetect score at week 10 of study period.	No